<DOC>
	<DOCNO>NCT00001854</DOCNO>
	<brief_summary>Chronic hepatitis C disease liver cause hepatitis C virus . The disease serious even fatal . Approximately 25 % patient chronic hepatitis C develop cirrhosis patient develop cancer liver liver failure . Presently disease treat combination alpha interferon peginterferon ( antiviral immune stimulate drug ) ribavirin ( antiviral drug ) . Alpha interferon give injection three time week whereas peginterferon give injection week . Ribavirin give tablet mouth twice day . The combination therapy give 6 month . About half patient give medication receive last benefit many patient respond well combination therapy . This study select 50 patient chronic hepatitis C respond combination therapy could stand side effect associate interferon peginterferon therapy . These subject evaluate undergo liver biopsy determine present liver condition . If select subject start single drug therapy ribavirin . The drug give orally twice day dose base patient 's body weight . The patient follow out-patient basis . They ask return regular check-ups blood test every 2 8 week duration study . After 6 month , medication stop adjust base result subject 's blood test ( liver enzymes ) . A response consider decrease 50 % initial liver enzyme ( alanine aminotransferase , ALT ) note . A complete response consider liver enzymes return normal level . Therapy discontinue 6 month patient respond . However , patient respond single drug therapy continue receive medication decrease dose . The patient remain appropriate dose 8 year repeat liver biopsy 2 , 4 8 year assess progress . This study determine long-term therapy ribavirin safe effective .</brief_summary>
	<brief_title>Long-Term Therapy With Ribavirin Chronic Hepatitis C</brief_title>
	<detailed_description>Up 50 patient chronic hepatitis C treat eight year ribavirin , orally administer antiviral agent . Patients choose moderate severe chronic hepatitis C previously fail sustained virological response combination alpha interferon ribavirin intolerant interferon therapy significant contraindication use interferon . After medical evaluation liver biopsy , patient begin receive ribavirin dose 1000 mg ( body weight less 75 K ) 1200 mg daily ( two three capsule 200 mg twice daily mouth ) . Patients follow therapy visit outpatient clinic medical interview , physical examination blood test 2 8 week interval . After six month , dose ribavirin stop adjust base upon change alanine aminotransferase ( ALT ) level compare average three value month 2 , 4 , 6 baseline level . A decrease 50 % consider partial biomedical response decrease within normal range consider complete biochemical response . In patient respond six month , therapy stop , whereas , patient respond , therapy continue decrease dose increment 200 mg per day every 6 month long biochemical response maintain . The minimal dose 400 mg per day . In patient response , therapy continue 8 year repeat liver biopsy evaluation 2 , 4 8 year . The primary criterion success therapy degree histologic improvement liver biopsy 2 , 4 8 year ; supportive , secondary criterion improvement ALT level symptoms do time point . This open-label pilot study allow therapy patient resistant form chronic hepatitis C address whether long-term therapy agent safe , well whether prolong monotherapy ribavirin lead sustained improvement serum ALT level , whether maintain use low dos ribavirin , whether improvement reflect amelioration underlie liver disease judge histologically .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>INCLUSION CRITERIA : Age 18 year , male female . Elevated alanine ( ALT ) asparate ( AST ) aminotransferase activity average least twice upper limit normal three determination take least one month apart previous 6 month . The mean three determination define `` baseline '' ALT AST level . Presence antiHCV HCV RNA serum test least previous six month . Evidence chronic hepatitis liver biopsy do within previous 12 month histology activity index least 6 ( maximum 22 ) . Contraindications use alpha interferon , either form specific contraindication use ( depression , psychiatric illness , neurological impairment , severe thrombocytopenia , autoimmune disease ) , history severe side effect intolerance previous course alpha interferon , lack sustain virological ( sustain lose HCV RNA serum six month stop treatment ) response adequate course ( 6 month ) combination alpha interferon ribavirin ( September 1 , 2003 ) combination peginterferon ribavirin . Written informed consent . INCLUSION CRITERIA FOR PATIENTS IN 98DK0003 : An important group patient enrol current study , patient participate Clinical Research Protocol 98DK0003 ( Combination alpha interferon longterm ribavirin patient chronic hepatitis C ) sustain virological response treatment . These patient eligible enroll current study finish therapy follow period trial . These patient fit inclusion criterion list one exception : patient receive ribavirin monotherapy part participation 98DK0003 . These patient eligible immediately enrol study without medicationfree period . EXCLUSION CRITERIA : Pregancy , woman childbearing potential , inability practice adequate contraception . Men spouses sexual partner childbearing potential also exclude unable practice adequate contraception . Significant systemic illness liver disease , include history congestive heart failure , cerebral vascular disease , renal failure ( creatinine clearance le 50 ml/min ) , angina pectoris . Patients abnormal stress test carotid untrasound enrol study . Preexisting anemia ( hematocrit le 32 % ) know history hemolytic anemia . Interferon immunosuppressive therapy within last 6 month . Evidence another form liver disease addition viral hepatitis , autoimmune alcoholic liver disease . Active recent ( within one year ) alcohol drug abuse psychiatric illness likely interfere compliance requirement safety monitoring study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 15, 2008</verification_date>
	<keyword>Ribavirin</keyword>
	<keyword>Liver Disease</keyword>
	<keyword>Antiviral Agent</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Chronic Hepatitis</keyword>
	<keyword>Iron</keyword>
	<keyword>Viral Hepatitis</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Hemolytic Anemia</keyword>
	<keyword>Hemolysis</keyword>
</DOC>